細胞・遺伝子治療製造サービス市場：サービスタイプ、技術タイプ、治療領域、用途、エンドユーザー別-2025～2030年世界予測

細胞・遺伝子治療製造サービス市場の2023年の市場規模は173億3,000万米ドルで、2024年には199億8,000万米ドル、CAGR15.81%で成長し、2030年には484億4,000万米ドルに達すると予測されています。

急速に進化する今日の状況において、細胞・遺伝子治療製造セクタは現代医療を変革する最前線にあります。前例のない科学的ブレークスルーと複雑な疾患に対処する緊急の必要性に後押しされて、この市場はダイナミックな革新と変革の可能性を特徴としています。このセグメントの製造サービスは、新たな治療法が安全かつ効率的でスケーラブルな方法で、研究から臨床応用へと確実に進むように設計されています。絶え間ない技術の進歩と強固な規制環境のもと、このセグメントの企業は、高品質の治療ソリューションに対する世界の需要の高まりに対応するため、その手法を絶えず改良しています。

メーカー各社は最新鋭の設備に投資し、生産プロセス全体を通じて優れた品質を維持するために最先端技術を導入しています。官民ともに個別化医療を重視する中、細胞・遺伝子治療技術への投資はかつてないほど高まっています。この包括的な概要では、最も重要な産業動向を探り、戦略立案に役立つ詳細な考察を提供することで、利害関係者が競争の激しい市場情勢に適応し、成功を収めるよう促しています。

広範な調査と先進的分析手法を組み合わせることで、本コンテンツは製造能力と市場動向に関して不可欠な文脈、背景、明確性を提供しています。革新的な解決策を求める緊急性は、学界、医薬品開発業務受託機関、大手製薬企業間の協力関係によって強調されており、それぞれが産業の成長と開発の強固なエコシステムに貢献しています。このような状況において、製造サービスの役割は、世界中の患者に革新的な臨床ソリューションを提供する上で極めて重要です。

細胞・遺伝子治療製造サービス市場の変革

細胞・遺伝子治療製造セクタは、産業のパラダイムを再構築し、急速な進歩を促す変革的なシフトを経験しています。ここ数年の間に、治療法の開発、製造、流通の基本的な性質が全面的に見直され、従来の生物製剤製造から高度に専門化された治療プラットフォームへの移行が進んでいます。企業は革新的な技術、先進的自動化、デジタル統合を活用し、製造プロセスの合理化、一貫性の確保、全体的な安全性の向上を図っています。この変革はまた、こうした先駆的な治療に伴って規制当局のモニタリングの目が厳しくなり、データの完全性、再現性、品質管理により高いレベルを求めるようになったことも拍車をかけています。

プロセス開発における絶え間ない革新は、スケーラビリティと効率の限界を押し広げつつあります。製造業者は現在、大規模な商業生産要件と並行して、小バッチの臨床生産に対応することが課題となっています。技術統合が主流になるにつれて、プロセスは、個別化治療に必要な柔軟性を具現化し、オーダーメイドの治療アプローチに適応できるようになってきています。さらに、バイオテクノロジー企業、学術研究機関、規制当局間の戦略的提携や協力関係により、技術移転や知識の共有が大幅に促進され、その結果、より機敏な製造方法が実現されています。

高性能・スクリーニング法の導入から堅牢な品質管理枠組みの採用まで、このセグメントの技術力は急速に拡大しています。幹細胞研究や遺伝子編集手法の進歩とともに個別化調査の需要が高まる中、産業はより効率的で信頼性が高く、拡大性のある製造モデルへの道を歩んでいます。こうした変革的なシフトは、この産業が先進的イノベーションのネットワークへと進化していることを裏付けるものであり、そこではオペレーションの卓越性が、成長を維持し、世界中で患者の転帰を改善するために不可欠となっています。

差別化された市場分析のための主要セグメンテーション洞察

細胞・遺伝子治療製造サービスの複雑さは、市場がセグメント化された様々な側面を検討することで理解できます。分析・品質管理サービス、セルバンキングサービス、コンサルティングサービス、充填・仕上げサービス、GMP製造サービス、プロセス開拓サービス、薬事サポートサービス、サプライチェーン・物流サービス、技術移転サービス、ベクタ製造サービスなどのカテゴリーにわたって市場が調査されるため、サービスタイプが分析の主要な促進要因となっています。これらの各サービスは、効率的な生産スケジュールを維持しながら、可能な限り高い水準で治療が生産されることを保証する上で、極めて重要な役割を担っています。

サービスベースのセグメンテーションに加え、技術的なニュアンスも市場の成長力学を読み解く上で不可欠です。徹底的な分析により、技術的展望は遺伝子編集技術とベクタ技術に分けられます。遺伝子編集では、CRISPR/Cas9、転写活性化因子様エフェクタヌクレアーゼ、ジンクフィンガーヌクレアーゼなどのプラットフォームが、ゲノム構造の正確な改変を可能にし、それによって治療成果を高めるのに役立っています。ベクタ技術はさらに、非ウイルス性とウイルス性のプラットフォームに分けられます。非ウイルス性ベクタシステムには、カチオン性脂質、キトサンベースのベクタ、デンドリマー、無機ナノ粒子、リポソーム、裸のDNA/RNA、ペプチドベースのベクタ、高分子ベクタなどが含まれ、その安全性プロファイルと拡大性から高く評価されています。逆に、ウイルスベクタは、アデノ随伴ウイルスベクタ、アデノウイルスベクタ、単純ヘルペスウイルスベクタ、レトロウイルスベクタなどのレンズを通して検討され、それぞれがトランスダクション効率と標的デリバリーの点でユニークな利点を提供しています。

治療セグメントのセグメンテーションは、心血管疾患、感染症、シングルユース性疾患、腫瘍学という文脈で市場を分析することで、洞察のもう一つの層を記載しています。心血管疾患では冠動脈疾患や心不全、感染症ではB型肝炎やHIV、シングルユース性疾患では嚢胞性線維症、血友病、鎌状赤血球貧血といった特定の疾患が、ニッチな疾患領域への詳細なフォーカスを示しています。腫瘍学も綿密にレビューされており、血液悪性腫瘍と固形腫瘍に注目されています。治療部門だけでなく、用途によるセグメンテーションにより、臨床製造と商業製造が区別され、それぞれ独自の運用戦略と品質保証プロトコルが必要とされます。

エンドユーザーによるプロファイリングは、市場を受託研究機関、病院クリニック、製薬・バイオテクノロジー企業、研究機関・学術機関などに区分し、分析の枠組みをさらに充実させています。このセグメンテーションの枠組みは、各市場セグメント特有の行動、ニーズ、成長の見込みを微妙に理解することで、利害関係者や意思決定者を強化し、より的を絞った戦略の策定と効果的な資源配分を可能にします。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患と遺伝性疾患の有病率の上昇
    • 先進的治療法の研究開発に対する政府の資金と助成金の増加
  • 抑制要因
    • 細胞・遺伝子治療の製造に関連する高い運用コスト
  • 機会
    • CRISPR技術の採用増加により、遺伝子工学サービスに新たな成長軌道が生まれている
    • バイオプロセス機器の技術的進歩は、効率的な生産プロセスへの道を切り開く
  • 課題
    • 細胞・遺伝子治療の製造における品質管理と汚染問題
• 市場セグメンテーション分析
  • サービスタイプ：さまざまな細胞株の安全な保管とアクセスを提供する細胞バンキングサービスの必要性
  • 技術タイプ：高いトランスフェクション効率と安定した遺伝子発現を目的としたウイルスベクタの増殖利用
  • 治療領域：造血悪性腫瘍と固形腫瘍の治療における腫瘍学における細胞遺伝子治療の意義
  • 用途：臨床製造の活用による前臨床検査と臨床検査の実施
  • エンドユーザー：革新的な治療法の開発と商業化のために、製薬企業とバイオテクノロジー企業全体で導入が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 細胞・遺伝子治療製造サービス市場：サービスタイプ別

• イントロダクション
• 分析と品質管理サービス
• 細胞バンキングサービス
• コンサルティングサービス
• 充填・仕上げサービス
• GMP製造サービス
• プロセス開発サービス
• 規制サポートサービス
• サプライチェーンと物流サービス
• 技術移転サービス
• ベクタ制作サービス

第7章 細胞・遺伝子治療製造サービス市場：技術タイプ別

• イントロダクション
• 遺伝子編集
  • クリスパー/Cas9
  • 転写活性化因子様エフェクタヌクレアーゼ
  • ジンクフィンガーヌクレアーゼ
• ベクトル
  • 非ウイルスベクタ
    • カチオン性脂質
    • キトサンベースのベクタ
    • デンドリマー
    • 無機ナノ粒子
    • リポソーム
    • ネイキッドDNA/RNA
    • ペプチドベースのベクタ
    • ポリマーベクタ
  • ウイルスベクタ
    • アデノ随伴ウイルス（AAV）ベクタ
    • アデノウイルスベクタ
    • 単純ヘルペスウイルス（HSV）ベクタ
    • レトロウイルスベクタ

第8章 細胞・遺伝子治療製造サービス市場：治療領域別

• イントロダクション
• 心血管疾患
  • 冠動脈疾患
  • 心不全
• 感染症
  • B型肝炎
  • HIV
• 単一遺伝子疾患
  • 嚢胞性線維症
  • 血友病
  • 鎌状赤血球貧血
• 腫瘍学
  • 造血悪性腫瘍
  • 固形腫瘍

第9章 細胞・遺伝子治療製造サービス市場：用途別

• イントロダクション
• 臨床製造
• 商業製造

第10章 細胞・遺伝子治療製造サービス市場：エンドユーザー別

• イントロダクション
• 契約研究機関
• 病院とクリニック
• 製薬・バイオテクノロジー企業
• 研究機関と学術機関

第11章 南北アメリカの細胞・遺伝子治療製造サービス市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の細胞・遺伝子治療製造サービス市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの細胞・遺伝子治療製造サービス市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Advanced BioScience Laboratories, Inc. by Institut Merieux
• AGC Biologics
• AmplifyBio
• Bio-Techne Corporation
• C.H. Boehringer Sohn AG & Co. KG
• Catalent, Inc.
• Cell Therapies Pty Ltd.
• Cell-Easy
• Charles River Laboratories International, Inc.
• Danaher Corporation
• eXmoor Pharma Concepts Limited
• FUJIFILM Diosynth BIoTechnologies
• Genezen Laboratories, Inc.
• Laboratory Corporation of America Holdings
• Lonza Group AG
• Merck KGaA
• Miltenyi BIoTec B.V. & Co. KG
• Minaris Regenerative Medicine GmbH by Resonac Corporation
• Nikon Corporation
• Novartis AG
• Oxford Biomedica PLC
• ProPharma Group Holdings, LLC
• Recipharm AB
• Samsung Biologics Co., Ltd.
• SGS S.A.
• STEMCELL Technologies Inc.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• uBriGene Biosciences Inc.
• WuXi AppTec Co., Ltd.

LIST OF FIGURES

• FIGURE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET MULTI-CURRENCY
• FIGURE 2. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET MULTI-LANGUAGE
• FIGURE 3. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH PROCESS
• FIGURE 4. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET DYNAMICS
• TABLE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 59. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 60. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 62. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 63. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 65. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 66. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 67. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 68. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 69. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 71. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 72. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 73. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 74. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 75. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 76. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 77. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 78. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 83. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 85. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 86. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 87. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 88. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 89. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 90. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 91. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 92. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 98. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 99. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 100. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 101. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 102. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 103. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 104. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 105. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 109. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 111. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 112. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 113. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 114. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 115. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 116. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 117. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 118. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 124. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 125. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 126. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 127. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 128. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 129. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 130. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 131. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 135. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 137. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 138. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 139. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 140. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 141. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 142. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 143. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 145. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 148. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 152. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 154. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 155. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 156. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 157. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 158. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 159. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 162. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 163. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 164. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 165. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 166. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 167. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 168. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 169. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 170. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 171. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 172. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 173. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 175. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 176. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 178. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 179. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 180. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 181. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 182. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 183. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 184. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 185. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 189. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 191. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 192. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 193. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 194. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 195. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 196. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 197. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 198. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 199. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 202. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 204. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 205. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 206. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 207. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 208. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 209. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 210. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 211. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 212. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 214. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 215. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 217. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 218. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 219. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 220. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 221. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 222. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 223. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 224. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 225. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 226. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 227. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 228. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 229. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 230. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 231. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 232. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 233. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 234. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 235. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 236. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 237. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 238. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 239. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 240. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 241. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 242. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 243. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 244. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 245. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 246. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 247. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 248. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 249. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 250. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 251. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 252. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 253. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 254. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 255. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 256. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 257. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 258. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 259. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 260. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
• TABLE 261. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 262. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 263. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 264. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 265. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 266. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 267. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 268. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2030 (USD MILLION)
• TABLE 269. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2030 (USD MILLION)
• TABLE 270. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 271. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
• TABLE 272. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC

The Cell & Gene Therapy Manufacturing Services Market was valued at USD 17.33 billion in 2023 and is projected to grow to USD 19.98 billion in 2024, with a CAGR of 15.81%, reaching USD 48.44 billion by 2030.

In today's rapidly evolving landscape, the cell and gene therapy manufacturing sector is at the forefront of revolutionizing modern medicine. Driven by unprecedented scientific breakthroughs and an urgent need to address complex diseases, this market is characterized by its dynamic innovation and transformative potential. The manufacturing services in this sector are designed to ensure that emerging therapies progress from research to clinical application in safe, efficient, and scalable ways. With constant technological advancements and a robust regulatory environment, companies in this field are continually refining their methods to meet increasing global demand for high-quality therapeutic solutions.

Manufacturers are investing in state-of-the-art facilities and integrating cutting-edge technology to maintain superior quality throughout the production process. As both the private and public sectors place greater emphasis on personalized healthcare, investment in cell and gene therapy technology has never been higher. This comprehensive summary explores the most significant industry trends and provides detailed insights that are instrumental for strategic planning, urging stakeholders to adapt and thrive in a competitive market landscape.

By combining extensive research with advanced analytical methodologies, the content here offers essential context, background, and clarity regarding manufacturing capabilities and market trends. The urgency for innovative solutions is underscored by collaborations between academia, contract research organizations, and large pharmaceutical companies, each contributing to a robust ecosystem of industry growth and development. In this context, the role of manufacturing services is pivotal to the delivery of transformative clinical solutions to patients around the world.

Transformative Shifts in the Cell & Gene Therapy Manufacturing Landscape

The cell and gene therapy manufacturing sector is experiencing transformative shifts that are reshaping the industry paradigm and driving rapid advancements. Over the past several years, the fundamental nature of how therapies are developed, produced, and distributed has undergone a complete overhaul, marking a transition from traditional biologics manufacturing to highly specialized therapeutic platforms. Companies are harnessing innovative technologies, advanced automation, and digital integration to streamline production processes, ensure consistency, and improve overall safety. This transformation is also spurred by the heightened regulatory scrutiny that now accompanies these pioneering treatments, with regulators demanding higher levels of data integrity, reproducibility, and quality control.

Continuous innovation in process development is pushing the boundaries of scalability and efficiency. Manufacturers are now challenged to accommodate small-batch clinical production alongside large-scale commercial manufacturing requirements. As technological integration becomes mainstream, processes are increasingly becoming adaptable to a tailored therapeutic approach, embodying flexibility that is necessary for personalized treatments. Additionally, strategic partnerships and collaborations between biotech companies, academic research institutions, and regulatory bodies have significantly expedited technology transfer and knowledge sharing, which in turn have led to more agile production practices.

From the incorporation of high-throughput screening methods to the adoption of robust quality control frameworks, the sector's technological capability is expanding rapidly. As the demand for personalized therapies grows in tandem with advancements in stem cell research and gene editing methodologies, the industry is charting a course towards more efficient, reliable, and scalable manufacturing models. These transformative shifts underscore the sector's evolution into a sophisticated network of innovation where operational excellence is critical for sustaining growth and improving patient outcomes worldwide.

Key Segmentation Insights for a Differentiated Market Analysis

The intricacies of cell and gene therapy manufacturing services can be understood by examining the various dimensions through which the market has been segmented. Service types are a primary driver for analysis, as the market is examined across categories such as analytical and quality control services, cell banking services, consulting services, fill and finish services, GMP manufacturing services, process development services, regulatory support services, supply chain and logistics services, technology transfer services, and vector production services. Each of these service offerings plays a crucial role in ensuring that therapies are produced to the highest possible standards while maintaining efficient production timelines.

In addition to service-based segmentation, technological nuances are integral to deciphering the market's growth dynamics. A thorough analysis divides the technological landscape into gene editing and vector technologies. Within gene editing, platforms such as CRISPR/Cas9, transcription activator-like effector nucleases, and zinc finger nucleases are instrumental in allowing precise modifications in the genomic structure, thereby enhancing therapy outcomes. Vector technologies are further dissected into non-viral and viral platforms. Non-viral vector systems, which include cationic lipids, chitosan-based vectors, dendrimers, inorganic nanoparticles, liposomes, naked DNA/RNA, peptide-based vectors, and polymeric vectors, are celebrated for their safety profile and scalability. Conversely, viral vectors are examined through the lens of adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, and retrovirus vectors, each offering unique advantages in terms of transduction efficiency and targeted delivery.

Therapeutic area segmentation provides another layer of insight, with the market being analyzed in the contexts of cardiovascular diseases, infectious diseases, monogenic disorders, and oncology. Specific conditions such as coronary artery disease and heart failure within cardiovascular diseases, hepatitis B and HIV within infectious diseases, and cystic fibrosis, hemophilia, and sickle cell anemia among monogenic disorders illustrate the detailed focus on niche disease areas. Oncology is also meticulously reviewed, with attention distributed between hematological malignancies and solid tumors. Beyond therapeutic divisions, a further segmentation based on application distinguishes between clinical manufacturing and commercial manufacturing, each necessitating its own set of operational strategies and quality assurance protocols.

Profiling based on end-user further enriches the analytical framework, as the market is segmented across contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes and academic institutions. This segmentation framework empowers stakeholders and decision-makers by providing a nuanced understanding of each market segment's unique behaviors, needs, and growth prospects, thereby enabling more targeted strategy formulations and effective resource allocation.

Based on Service Type, market is studied across Analytical & Quality Control Services, Cell Banking Services, Consulting Services, Fill & Finish Services, GMP Manufacturing Services, Process Development Services, Regulatory Support Services, Supply Chain & Logistics Services, Technology Transfer Services, and Vector Production Services.

Based on Technology Type, market is studied across Gene Editing and Vectors. The Gene Editing is further studied across CRISPR/Cas9, Transcription Activator-Like Effector Nucleases, and Zinc Finger Nucleases. The Vectors is further studied across Non-Viral Vectors and Viral Vectors. The Non-Viral Vectors is further studied across Cationic Lipids, Chitosan-Based Vectors, Dendrimers, Inorganic Nanoparticles, Liposomes, Naked DNA/RNA, Peptide-Based Vectors, and Polymeric Vectors. The Viral Vectors is further studied across Adeno-Associated Virus (AAV) Vectors, Adenovirus Vectors, Herpes Simplex Virus (HSV) Vectors, and Retrovirus Vectors.

Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Infectious Diseases, Monogenic Disorders, and Oncology. The Cardiovascular Diseases is further studied across Coronary Artery Disease and Heart Failure. The Infectious Diseases is further studied across Hepatitis B and HIV. The Monogenic Disorders is further studied across Cystic Fibrosis, Hemophilia, and Sickle Cell Anemia. The Oncology is further studied across Hematological Malignancies and Solid Tumors.

Based on Application, market is studied across Clinical Manufacturing and Commercial Manufacturing.

Based on End-User, market is studied across Contract Research Organizations, Hospitals & Clinics, Pharmaceutical & Biotech Companies, and Research Institutes & Academic Institutions.

Regional Insights: Assessing the Global Market Landscape

Analyzing the market through a global lens reveals distinctive trends and competitive dynamics across various regions. In the Americas, advanced infrastructure, a conducive regulatory environment, and a robust network of clinical research institutions are creating a fertile ground for the adoption and scaling of cell and gene therapy technologies. Market participants in this region benefit from a strong focus on innovation supported by well-funded academic and private research initiatives, which continuously drive breakthrough developments.

The combined territory of Europe, the Middle East, and Africa has emerged as a vital hub for both innovation and regulatory prowess. In Europe, rigorous standards enforced by regulatory bodies have led to the development of high-quality manufacturing practices, ensuring that therapies adhere to the most stringent safety protocols. Meanwhile, emerging markets within the Middle East and Africa are progressively investing in state-of-the-art manufacturing facilities and seeking collaborations with global industry leaders to uplift their capabilities and expertise in cell and gene therapy production.

Asia-Pacific has become a powerhouse in the global pharmaceutical landscape, largely due to its rapid economic growth, increased investment in technology, and an accelerating pace of regulatory harmonization. Countries in this region are strategically focused on enhancing their capabilities in both clinical and commercial manufacturing, which is attracting substantial foreign investments and forging strategic alliances with international manufacturers. Such regional insights illustrate that while each region exhibits its own distinct set of opportunities and challenges, the overarching trend is one of collaborative growth and robust market expansion worldwide.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Industry Leaders: A Deep Dive into Key Company Performance Drivers

A critical component of uncovering emerging trends in the cell and gene therapy manufacturing space involves a close examination of the actions and performance of key companies. Research and development efforts by entities such as Advanced BioScience Laboratories, Inc. by Institut Merieux and AGC Biologics have set the benchmark for quality and innovation across the industry. Companies including AmplifyBio, Bio-Techne Corporation, and C.H. Boehringer Sohn AG & Co. KG have further contributed to the progression of manufacturing technologies through advanced analytical capabilities and seamless integration of quality control systems.

Other market leaders such as Catalent, Inc. and Cell Therapies Pty Ltd. are not only enhancing process optimization but are also pioneering breakthroughs in cell banking and process development strategies. Firms like Cell-Easy and Charles River Laboratories International, Inc. have become synonymous with reliable supply chain management that supports wide-ranging production demands. The strategic insights from heavyweight players such as Danaher Corporation, eXmoor Pharma Concepts Limited, FUJIFILM Diosynth Biotechnologies, and Genezen Laboratories, Inc. exemplify the drive towards harnessing next-generation manufacturing technologies to ensure sustained growth.

The presence of major corporations like Laboratory Corporation of America Holdings, Lonza Group AG, Merck KGaA, and Miltenyi Biotec B.V. & Co. KG further reinforces industry confidence by demonstrating long-standing expertise in optimizing and scaling manufacturing processes. In addition, influential market players such as Minaris Regenerative Medicine GmbH by Resonac Corporation, Nikon Corporation, Novartis AG, Oxford Biomedica PLC, and ProPharma Group Holdings, LLC have seamlessly integrated innovative systems that optimize quality, compliance, and production throughput. Strategic insights offered by companies like Recipharm AB, Samsung Biologics Co., Ltd., SGS S.A., STEMCELL Technologies Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., uBriGene Biosciences Inc., and WuXi AppTec Co., Ltd. highlight the importance of effort in aligning technological advancements with operational efficiency. Collectively, these key companies set a robust foundation for the sector by championing rigorous quality standards and embracing innovation at every stage of the product lifecycle.

The report delves into recent significant developments in the Cell & Gene Therapy Manufacturing Services Market, highlighting leading vendors and their innovative profiles. These include Advanced BioScience Laboratories, Inc. by Institut Merieux, AGC Biologics, AmplifyBio, Bio-Techne Corporation, C.H. Boehringer Sohn AG & Co. KG, Catalent, Inc., Cell Therapies Pty Ltd., Cell-Easy, Charles River Laboratories International, Inc., Danaher Corporation, eXmoor Pharma Concepts Limited, FUJIFILM Diosynth Biotechnologies, Genezen Laboratories, Inc., Laboratory Corporation of America Holdings, Lonza Group AG, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Minaris Regenerative Medicine GmbH by Resonac Corporation, Nikon Corporation, Novartis AG, Oxford Biomedica PLC, ProPharma Group Holdings, LLC, Recipharm AB, Samsung Biologics Co., Ltd., SGS S.A., STEMCELL Technologies Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., uBriGene Biosciences Inc., and WuXi AppTec Co., Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are urged to leverage emerging trends by embracing collaborative innovation and agile manufacturing protocols to remain competitive in an increasingly complex market. It is recommended to invest in advanced technological platforms for process optimization that not only reduce production time but also enhance product quality and consistency. Leaders should prioritize the adoption of digitalization solutions, including data analytics and automation, to streamline validation processes and improve overall operational efficiency. By integrating these systems, companies can foresee challenges in real-time and achieve a more responsive manufacturing ecosystem.

Furthermore, fostering robust partnerships with regulatory bodies enables a proactive approach in aligning production standards with evolving global requirements. This can be achieved by developing comprehensive training programs that ensure staff remains adept at utilizing cutting-edge technology while adhering to stringent quality control measures. A renewed focus on technology transfer and strategic collaborations across cross-functional teams will also help in bridging the gap between clinical research and commercial production capabilities. Furthermore, diversifying service portfolios by incorporating end-to-end manufacturing solutions can help cater to the varying needs of both clinical and commercial manufacturing segments.

Industry leaders must also consider environmental sustainability as an integral part of manufacturing excellence. Investing in green technologies and reducing resource wastage during production not only contributes to corporate responsibility but also enhances long-term operational viability. In conclusion, a multifaceted approach that intertwines process innovation, regulatory engagement, staff training, and sustainability investments will serve as the cornerstone for achieving both immediate and long-term success in the cell and gene therapy manufacturing domain.

Conclusion: Charting the Path Forward in Cell & Gene Therapy Manufacturing

In summary, the evolution of cell and gene therapy manufacturing services is marked by significant shifts that are transforming how therapies are developed and delivered. The integration of advanced technologies with rigorous quality control, the strategic segmentation of services, and the dynamic interplay among key market regions provide a detailed roadmap for industry advancement. The narrative outlined earlier reinforces that strategic agility, through innovative process development and regulatory alignment, is the cornerstone for remaining competitive. As the field continues to mature, organizations that adopt a forward-thinking approach will be best positioned to embrace new opportunities and overcome emerging challenges.

The collective insights presented in this review illuminate how meticulous segmentation and regional analysis are critical in mapping out growth strategies. Equally, the actions of leading companies offer invaluable benchmarks and best practices that can be replicated for enhanced production efficiency and market penetration. By uniting scientific innovation with strategic planning, the path forward becomes clearer, offering a promise of groundbreaking therapies that meet the urgent demands of healthcare across the globe. The consolidated message is one of resilience and proactive adaptation - qualities that are essential for transforming challenges into opportunities in an ever-changing regulatory and technological landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic diseases and genetic disorders
    • 5.1.1.2. Increase in government funding and grants for research and development of advanced therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High operational costs associated with cell & gene therapy manufacturing
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising adoption of CRISPR technology providing a new growth trajectory in genetic engineering services
    • 5.1.3.2. Technological advancements in bioprocessing equipment create avenues for efficient production processes
  • 5.1.4. Challenges
    • 5.1.4.1. Quality control and contamination issues in cell & gene therapy production
• 5.2. Market Segmentation Analysis
  • 5.2.1. Service Type: Need for cell banking services for providing secure storage and access to various cell lines
  • 5.2.2. Technology Type: Proliferating usage of the viral vectors for their high transfection efficiency and stable gene expression
  • 5.2.3. Therapeutic Area: Significance of cell gene therapy in oncology for treating hematological malignancies and solid tumors
  • 5.2.4. Application: Utilization of clinical manufacturing to enable preclinical testing and clinical trials
  • 5.2.5. End-User: Rising adoption across pharmaceutical & biotech companies for the development and commercialization of innovative therapies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cell & Gene Therapy Manufacturing Services Market, by Service Type

• 6.1. Introduction
• 6.2. Analytical & Quality Control Services
• 6.3. Cell Banking Services
• 6.4. Consulting Services
• 6.5. Fill & Finish Services
• 6.6. GMP Manufacturing Services
• 6.7. Process Development Services
• 6.8. Regulatory Support Services
• 6.9. Supply Chain & Logistics Services
• 6.10. Technology Transfer Services
• 6.11. Vector Production Services

7. Cell & Gene Therapy Manufacturing Services Market, by Technology Type

• 7.1. Introduction
• 7.2. Gene Editing
  • 7.2.1. CRISPR/Cas9
  • 7.2.2. Transcription Activator-Like Effector Nucleases
  • 7.2.3. Zinc Finger Nucleases
• 7.3. Vectors
  • 7.3.1. Non-Viral Vectors
    • 7.3.1.1. Cationic Lipids
    • 7.3.1.2. Chitosan-Based Vectors
    • 7.3.1.3. Dendrimers
    • 7.3.1.4. Inorganic Nanoparticles
    • 7.3.1.5. Liposomes
    • 7.3.1.6. Naked DNA/RNA
    • 7.3.1.7. Peptide-Based Vectors
    • 7.3.1.8. Polymeric Vectors
  • 7.3.2. Viral Vectors
    • 7.3.2.1. Adeno-Associated Virus (AAV) Vectors
    • 7.3.2.2. Adenovirus Vectors
    • 7.3.2.3. Herpes Simplex Virus (HSV) Vectors
    • 7.3.2.4. Retrovirus Vectors

8. Cell & Gene Therapy Manufacturing Services Market, by Therapeutic Area

• 8.1. Introduction
• 8.2. Cardiovascular Diseases
  • 8.2.1. Coronary Artery Disease
  • 8.2.2. Heart Failure
• 8.3. Infectious Diseases
  • 8.3.1. Hepatitis B
  • 8.3.2. HIV
• 8.4. Monogenic Disorders
  • 8.4.1. Cystic Fibrosis
  • 8.4.2. Hemophilia
  • 8.4.3. Sickle Cell Anemia
• 8.5. Oncology
  • 8.5.1. Hematological Malignancies
  • 8.5.2. Solid Tumors

9. Cell & Gene Therapy Manufacturing Services Market, by Application

• 9.1. Introduction
• 9.2. Clinical Manufacturing
• 9.3. Commercial Manufacturing

10. Cell & Gene Therapy Manufacturing Services Market, by End-User

• 10.1. Introduction
• 10.2. Contract Research Organizations
• 10.3. Hospitals & Clinics
• 10.4. Pharmaceutical & Biotech Companies
• 10.5. Research Institutes & Academic Institutions

11. Americas Cell & Gene Therapy Manufacturing Services Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Cell & Gene Therapy Manufacturing Services Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Cell & Gene Therapy Manufacturing Services Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. OmniaBio revolutionizes cell & gene therapy manufacturing with AI-driven facility in Ontario,
  • 14.3.2. eXmoor Pharma and Virica Biotech are collaborating to enhance the manufacturing efficiency of adeno-associated vectors
  • 14.3.3. Strategic collaboration between SK pharmteco and Cryoport revolutionizes cell & gene therapy logistics and manufacturing
  • 14.3.4. eXmoor Pharma's MIA(IMP) license fuels expansion in GMP-grade cell & gene therapy manufacturing
  • 14.3.5. Cryoport and Minaris unite to revolutionize cell & gene therapy with integrated services
  • 14.3.6. Merck KGaA's acquisition of Mirus Bio enhances viral vector manufacturing for cell & gene therapies
  • 14.3.7. ProPharma and PBL collaborate on innovative cell & gene therapy manufacturing
  • 14.3.8. Memel Biotech revolutionizes cell & gene therapy manufacturing with new Klaipeda facility launch
  • 14.3.9. FUJIFILM invests USD 200 million to increase cell therapy CDMO capabilities amid market surge
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Charles River Laboratories International, Inc.
  • 14.4.2. Lonza Group AG
  • 14.4.3. Takara Bio Inc.
  • 14.4.4. Merck KGaA

Companies Mentioned

• 1. Advanced BioScience Laboratories, Inc. by Institut Merieux
• 2. AGC Biologics
• 3. AmplifyBio
• 4. Bio-Techne Corporation
• 5. C.H. Boehringer Sohn AG & Co. KG
• 6. Catalent, Inc.
• 7. Cell Therapies Pty Ltd.
• 8. Cell-Easy
• 9. Charles River Laboratories International, Inc.
• 10. Danaher Corporation
• 11. eXmoor Pharma Concepts Limited
• 12. FUJIFILM Diosynth Biotechnologies
• 13. Genezen Laboratories, Inc.
• 14. Laboratory Corporation of America Holdings
• 15. Lonza Group AG
• 16. Merck KGaA
• 17. Miltenyi Biotec B.V. & Co. KG
• 18. Minaris Regenerative Medicine GmbH by Resonac Corporation
• 19. Nikon Corporation
• 20. Novartis AG
• 21. Oxford Biomedica PLC
• 22. ProPharma Group Holdings, LLC
• 23. Recipharm AB
• 24. Samsung Biologics Co., Ltd.
• 25. SGS S.A.
• 26. STEMCELL Technologies Inc.
• 27. Takara Bio Inc.
• 28. Thermo Fisher Scientific Inc.
• 29. uBriGene Biosciences Inc.
• 30. WuXi AppTec Co., Ltd.